Dr. Yazan Samhouri, MD

Dr. Samhouri practices at Allegheny General Hospital in Pittsburgh, Pennsylvania, part of Highmark Health.

Dr. Samhouri's NPI, 1124433198, was assigned on June 27, 2014. Dr. Samhouri holds Pennsylvania license MD475066.

Dr. Samhouri's primary practice is Allegheny General Hospital, at 320 East North Avenue, Pittsburgh, PA 15212 in Allegheny County. The practice phone is (412) 359-3131.

Dr. Samhouri's primary practice is Allegheny General Hospital in Pittsburgh, Pennsylvania, part of Highmark Health. Dr. Samhouri is also affiliated with West Penn Hospital. The medical group on file is AHN Primary Care - Family Med Associates at H+W Pavilion Bethel Park. Dmand AI also links Dr. Samhouri to 2 more hospitals, 1 breast imaging center, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Samhouri practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Samhouri's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Samhouri is board certified in hematology by the American Board of Internal Medicine. Dr. Samhouri is licensed in Pennsylvania.

CMS data shows 507 Medicare services from Dr. Samhouri across 8 procedure codes in 2024, for 138 Medicare patients. Medicare paid $48,611 for them.

CMS counts 138 Medicare patients who saw Dr. Samhouri in 2024. The largest group is 65 to 74, with 83 patients. 74% of them have high blood pressure, and 72% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Samhouri's median patient age at 64, with 43% women.

In 2024, Dr. Samhouri wrote 1,035 Medicare Part D claims for 131 patients. 83% of them were for generic drugs. CMS names the drug for 851 of them, across 23 drugs with 11 or more claims each, at $1,118,934 in total drug cost. In 2023, CMS named 521 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Samhouri for performance year 2024, reported through an alternative payment model (APM). Dr. Samhouri accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Samhouri as offering telehealth.

Dmand AI links 37 papers to Dr. Samhouri, published from 2016 to 2025. 2022 was the busiest year, with 8. The most frequent topics are Lymphoma, Antineoplastic Agents and Bone Marrow. Dr. Samhouri has published most often in J Hematol. Dr. Samhouri's most frequent co-authors are Cyrus Mohammad Ali Khan, MD, Salman M. Fazal, MD and Urwat Til Vusqa, MD.

Dmand AI links Dr. Samhouri to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Lymphoma, B-Cell, Marginal Zone and Burkitt Lymphoma.

CMS Open Payments shows 192 general payments to Dr. Samhouri from 33 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 40% of the total. ADC Therapeutics America, Inc. paid the most, $30,845.